Computational assessment of drug-induced effects on the electrocardiogram: From ion channel to body surface potentials

British Journal of Pharmacology

Volumn 168, Issue 3, 2013, Pages 718-733

  Zemzemi, Nejib ^a,b   Bernabeu, Miguel O ^a,d   Saiz, Javier ^c   Cooper, Jonathan ^a   Pathmanathan, Pras ^a   Mirams, Gary R ^a   Pitt Francis, Joe ^a   Rodriguez, Blanca ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INRIA   (France)

^c UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

computer simulation; drug; ECG modelling; hERG; QRS widening; QT prolongation; sodium blockers

Indexed keywords

BIOLOGICAL MARKER; ION CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; BODY SURFACE POTENTIAL; COMPUTER MODEL; ELECTROCARDIOGRAPHY; HEART ELECTROPHYSIOLOGY; IC 50; ION CONDUCTANCE; MATHEMATICAL MODEL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION;

ACTION POTENTIALS; COMPUTER SIMULATION; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HUMANS; MODELS, BIOLOGICAL; POTASSIUM CHANNEL BLOCKERS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 84872373202     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02200.x     Document Type: Article

References (86)

1. Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP, (2004). Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes. Fundam Clin Pharmacol 18: 139-151.
2. Adams CP, Brantner VV, (2006). Estimating the cost of new drug development: is it really 802 million? Health Aff 25: 420-428.
3. Aehlert B, (2006). Ecgs Made Easy. third edn. Elsevier: Mosby Jems.
4. Bernabeu MO, Bishop MJ, Pitt-Francis J, Gavaghan DJ, Grau V, Rodriguez B, (2008). High performance computer study of biological function in 3D heart models incorporating fibre orientation and realistic geometry at para-cellular resolution. Comput Cardiol 2008: 721-724.
5. Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MWT, Miyamoto Y, et al. (2006). Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 113: 338-344.
6. Bishop MJ, Hales P, Plank G, Gavaghan DJ, Scheider J, Grau V, (2009). Comparison of rule-based and DTMRI-derived fibre architecture in a whole rat ventricular computational model. Lect Notes Comput Sci 5528: 87-96.
7. Bordas R, Gillow K, Lou Q, Efimov I, Kohl P, Gavaghan D, et al. (2011). Full rabbit-specific ventricular model of cardiac electrophysiological function including specialized conduction system. Prog Biophys Mol Biol 107: 90-100.
8. Boulakia M, Cazeau S, Fernandez MA, Gerbeau JF, Zemzemi N, (2010). Mathematical modeling of electrocardiograms: a numerical study. Ann Biomed Eng 38: 1071-1097.
9. Brennan T, Fink M, Rodriguez B, (2009). Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. Eur J Pharm Sci 36: 62-77.
10. Chapelle D, Fernndez MA, Gerbeau JF, Moireau P, Sainte-Marie J, Zemzemi N, (2009). Numerical simulation of the electromechanical activity of the heart. In:, Ayache N, Delingette H, Sermesant M, (eds). Functional Imaging and Modeling of the Heart, Volume 5528 of Lecture Notes in Computer Science. Springer: Berlin, pp. 357-365.
11. Clancy CE, Rudy Y, (1999). Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature 400: 566-569.
12. Clancy CE, Rudy Y, (2001). Cellular consequences of herg mutations in the long qt syndrome: precursors to sudden cardiac death. Cardiovasc Res 50: 301-313.
13. Clements J, Nenonen J, Li PKJ, Horacek BM, (2004). Activation dynamics in anisotropic cardiac tissue via decoupling. Ann Biomed Eng 2: 984-990.
14. Clerc L, (1976). Directional differences of impulse spread in trabecular muscle from mammalian heart. J Physiol 255: 335-346.
15. Cooper J, (2009). Automatic Validation and Optimisation of Biological Models. DPhil Thesis, University of Oxford.
16. Corrias A, Jie X, Romero L, Bishop MJ, Bernabeu M, Pueyo E, et al. (2010). Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations. Philos Trans R Soc A 368: 3001-3025.
17. Curran ME, Splawski I, Timothy KW, Vincent GM, Green DE, Keating MT, (1995). A molecular basis for cardiac arrhythmia: herg mutations cause long qt syndrome. Cell 80: 795-803.
18. Davies MR, Mistry HB, Hussein L, Pollard CE, Valentin J-P, Swinton J, et al. (2012). An In silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. Am J Physiol Heart Circ Physiol 302: 466-480.
19. De Bruin ML, Pettersson M, Meyboom RHB, Hoes AW, Leufkens HGM, (2005). Anti-herg activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590-597.
20. Dux-Santoy L, Sebastian R, Felix-Rodriguez J, Ferrero J, Saiz J, (2011). Interaction of specialized cardiac conduction system with antiarrhythmic drugs: a simulation study. IEEE Trans Biomed Eng 58: 3475-3478.
21. Epstein BR, Foster KR, (1983). Anisotropy in the dielectric properties of skeletal muscle. Med Biol Eng Comput 21: 51-55.
22. Fletcher K, Shah RR, Thomas A, Tobin F, Rodriguez B, Mirams G, (2011). Novel approaches to assessing cardiac safety-proceedings of a workshop: regulators, industry and academia discuss the future of in silico cardiac modelling to predict the proarrhythmic safety of drugs. Drug Saf 34: 439-443.
23. Fossa AA, DePasquale MJ, Raunig DL, Avery MJ, Leishman DJ, (2002). The relationship of clinical qt prolongation to outcome in the conscious dog using a beat-to-beat qt-rr interval assessment. J Pharmacol Exp Ther 302: 828-833.
24. Frey P, (2001). Yams: a fully automatic adaptive isotropic surface remeshing procedure. Technical report 0252, INRIA-Rocquencourt, France.
25. George PL, Hecht F, Saltel E, (1990). Fully automatic mesh generator for 3d domains of any shape. Impact Comput Sci And Eng 2: 187-218.
26. Gima K, Rudy Y, (2002). Ionic current basis of electrocardiographic waveforms: a model study. Circ Res 90: 889.
27. Gintant G, (2011). An evaluation of herg current assay performance: translating preclinical safety studies to clinical qt prolongation. Pharmacol Ther 129: 109-119.
28. Glukhov AV, Fedorov VV, Lou Q, Ravikumar VK, Kalish PW, Schuessler RB, et al. (2010). Transmural dispersion of repolarization in failing and nonfailing human ventricle. Circ Res 106: 981-991.
29. Grandy SA, Howlett SE, (2006). Cardiac excitation-contraction coupling is altered in myocytes from aged male mice but not in cells from aged female mice. Am J Physiol Heart Circ Physiol 291: H2362-H2370.
30. Hancox JC, McPate MJ, El Harchi A, Zhang Y, (2008). The herg potassium channel and herg screening for drug-induced torsades de pointes. Pharmacol Ther 119: 118-132.
31. Hondeghem M, Carlsson M, Duker G, (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
32. ICH. E14 (2005). The clinical evaluation of qt/qtc interval prolongation and proarrhythmic potential for non-anti arrhythmic drugs. Technical report.
33. Janse MJ, Coronel R, Opthof T, Sosunov EA, Anyukhovsky EP, Rosen MR, (2012). Repolarization gradients in the intact heart: transmural or apico-basal? Prog Biophys Mol Biol 109: 6-15.
34. Karjalainen J, Viitasalo M, Manttari M, Manninen V, (1994). Relation between qt intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust qt interval values. J Am Coll Cardiol 23: 1547-1553.
35. Keller DUJ, Weiss DL, Doessel O, Seemann G, (2011). Influence of IKs Heterogeneities on the Genesis of the T-Wave: a computational evaluation. IEEE Trans Biomed Eng 99: 1-1.
36. Kohlhardt M, Bauer B, Krause H, Fleckenstein A, (1972). Differentiation of the transmembrane na and ca channels in mammalian cardiac fibres by the use of specific inhibitors. Pflugers Arch 335: 309-322.
37. Kowey PR, Malik M, (2007). The qt interval as it relates to the safety of non-cardiac drugs. Eur Heart J Suppl 9 (Suppl. G): G3.
38. Krikler DM, Curry PV, (1976). Torsade de pointes, an atypical ventricular tachycardia. Br Heart J 38: 117-120.
39. Lines GT, Buist ML, Grottum P, Pullan AJ, Sundnes J, Tveito A, (2003a). Mathematical models and numerical methods for the forward problem in cardiac electrophysiology. Comput Vis Sci 5: 215-239.
40. Lines GT, Grottum P, Tveito A, (2003b). Modeling the electrical activity of the heart: a bidomain model of the ventricles embedded in a torso. Comput Vis Sci 5: 195-213.
41. Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, et al. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol 154: 1427-1438.
42. Lu HR, Rohrbacher J, Vlaminckx E, Ammel KV, Yan G-X, Gallacher DJ, (2010). Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers. BJP 160: 60-76.
43. Mackin P, (2008). Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 23: S3-S14.
44. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ, (2002). Relation between qt and rr intervals is highly individual among healthy subjects: implications for heart rate correction of the qt interval. Heart 87: 220-228.
45. Malmivuo J, Plonsey R, (1995). Bioelectromagnetism. Principles and Applications of Bioelectric and Biomagnetic fields. Oxford University Press: New York.
46. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, et al. (2011). Simulation of multiple ion channel block provides improved early prediction of compounds clinical torsadogenic risk. Cardiovasc Res 91: 53-61.
47. Miura M, Ishide N, Oda H, Sakurai M, Shinozaki T, Takishima T, (1993). Spatial features of calcium transients during early and delayed afterdepolarizations. Am J Physiol Heart Circ Physiol 265: 439-444.
48. Moreno JD, Zhu Zi, Wang PC, Bankston JR, Jeng MT, Kang C, et al. (2011). A computational model predict the effects of class I anti-arrhythmic drugs on venticular rhythms. Sci Transl Med 3: 83-98
49. Niederer SA, Kerfoot E, Benson AP, Bernabeu MO, Bernus O, Bradley C, et al. (2011). Verification of cardiac tissue electrophysiology simulators using an n-version benchmark. Philosophical Transactions of the Royal Society A: mathematical. Phys Eng Sci 369: 4331-4351.
50. Noble D, (2008). Computational models of the heart and their use in assessing the actions of drugs. J Pharmacol Sci 107: 107-117.
51. Pathmanathan P, Bernabeu MO, Bordas R, Cooper J, Garny A, Pitt-Francis J, et al. (2010). A numerical guide to the solution of the bidomain equations of cardiac electrophysiology. Prog Biophys Mol Biol 102: 136-155.
52. Pitt-Francis J, Pathmanathan P, Bernabeu MO, Bordas R, Cooper J, Fletcher AG, et al. (2009). Chaste: a test-driven approach to software development for biological modelling. Comput Phys Commun 180: 2452-2471.
53. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin J, et al. (2010). An introduction to qt interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
54. Potse M, Dube B, Gulrajani M, (2003). ECG simulations with realistic human membrane, heart, and torso models. In Proceedings of the 25th Annual Intemational Conference of the IEEE EMBS, pages 70-77.
55. Potse M, Dube B, Vinet A, (2009). Cardiac anisotropy in boundary-element models for the electrocardiogram. Med Biol Eng Comput 47: 719-729.
56. Pueyo E, Husti Z, Hornyik T, Baczko I, Laguna P, Varro A, et al. (2010). Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk. Am J Physiol Heart Circ Physiol 298: H1577-1587.
57. Pugsley MK, Authier S, Curtis MJ, (2008). Principles of safety pharmacology. Br J Pharmacol 154: 1382-1399.
58. Pullan AJ, Buist ML, Cheng LK, (2005). Mathematically Modelling the Electrical Activity of the Heart. From Cell to Body Surface and Back Again. World Scientific Publishing Co. Pte. Ltd.: Singapore.
59. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F, (2005). Qt prolongation through herg k+ channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 25: 133-166.
60. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical qt interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
61. Romero L, Pueyo E, Fink M, Rodriguez B, (2009). Impact of ionic current variability on human ventricular cellular electrophysiology. Am J Physiol Heart Circ Physiol 297: 14-36.
62. Rush S, Driscoll DA, (1969). Eeg electrode sensitivity-an application of reciprocity. IEEE Trans Biomed Eng 1: 15-22.
63. Saiz J, Tena G, Monserrat M, Ferrero JM, Cardona K, Chorro J, (2011). Effects of the antiarrhythmic drug dofetilide on transmural dispersion of repolarization in ventriculum. A computer modeling study. IEEE Trans Biomed Eng 58: 43-53.
64. Salata JJ, Wasserstrom JA, (1988). Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. Circ Res 62: 324-337.
65. Sale H, Wang J, O'Hara TJ, Tester DJ, Phartiyal P, He JQ, et al. (2008). Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with long-QT syndrome. Circ Res 103: 81-95.
66. Sanchez C, Corrias A, Bueno-Orovio A, Davies M, Swinton J, Jacobson I, et al. (2012). The Na+/K+ pump is an important modulator of refractoriness and rotor dynamics in human atrial tissue. AJP 302: 146-159.
67. Sanguinetti MC, Mitcheson JS, (2005). Predicting drug-herg channel interactions that cause acquired long qt syndrome. Trends Pharmacol Sci 26: 119-124.
68. Schwan HP, Kay CF, (1957). The conductivity of living tissues. Ann N Y Acad Sci 65: 1007-1013.
69. Shimizu W, Antzelevitch C, (1997). Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in lqt2 and lqt3 models of the long-qt syndrome. Circulation 96: 2038-2047.
70. Sims C, Reisenweber S, Viswanathan PC, Choi BR, Walker WH, Salama G, (2008). Sex, age, and regional differences in l-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with drug-induced long qt type 2. Circ Res 102: 86-100.
71. Soubert A, Helmlinger G, Dumotier B, Bibas R, Georgieva A, (2009). Modeling and simulation of preclinical cardiac safety: towards an integrative framework. Drug Metab Pharmacokinet 24: 76-90.
72. Straus SMJM, Sturkenboom MCJM, Bleumink GS, Dieleman JP, Lei J, Graeff PA, et al. (2005). Non-cardiac qtc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 26: 2007-2012.
73. Sundnes J, Lines GT, Cai X, Nielsen BF, Mardal KA, Tveito A, (2006). Computing the Electrical Activity in the Heart. Springer-Verlag: Berlin Heidelberg, New York.
74. Ten Tusscher K, Panfilov AV, (2006). Cell model for effcient simulation of wave propagation in human ventricular tissue under normal and pathological conditions. Phys Med Biol 51: 6141-6156.
75. Thummel KE, Wilkinson GR, (1998). In vitro and in vivo drug interactions involving human cyp3a. Annu Rev Pharmacol Toxicol 38: 389-430.
76. Tung L, (1978). A bi-domain model for describing ischemic myocardial D-C potentials. PhD thesis, MIT.
77. Valentin JP, Hammond T, (2008). Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 58: 77-87.
78. Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem LM, (2004). Review of the predictive value of the langendorff heart model (screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 49: 171-181.
79. Vandenberg JI, Walker BD, Campbell TJ, (2001). Herg k+ channels: friend and foe. Trends Pharmacol Sci 22: 240-246.
80. Verkerk AO, Wilders R, Veldkamp MW, Geringel W, Kirkels JH, Tan HL, (2005). Gender disparities in cardiac cellular electrophysiology and arrhythmia susceptibility in human failing ventricular myocytes. Int Heart J 46: 1105-1118.
81. Volders PGA, Vos MA, Szabo B, Sipido KR, De Groot SH, Gorgels APM, et al. (2000). Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 46: 376-392.
82. Yan GX, Lankipalli RS, Burke JF, Musco S, Kowey PR, (2003). Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol 42: 401-409.
83. Yang T, Roden MD, (1996). Extracellular potassium modulation of drug block of ikr: implications for torsade de pointes and reverse use dependence. Circulation 93: 407-411.
84. Yap YG, Camm AJ, (2003). Drug induced QT prolongation and torsades de pointes. BMJ 89: 1363-1372.
85. Zemzemi N, (2009). Etude theorique et numerique de l'activite electrique du Coeur: application aux electrocardiogrammes. DPhil Thesis. University of Paris-Sud, Paris-IX. Available at: http://tel.archives-ouvertes.fr/tel-00470375/ en/ (accessed 14 December 2009).
86. Zemzemi N, Bernabeu MO, Saiz J, Rodriguez B, (2011). LCNS. Springer-Verlag: Berlin-Heidelberg.